OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

B. Hsu; S. Sheng; M.E. Weinblatt; J.S. Smolen

doi:10.1136/annrheumdis-2012-eular.1708

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

FRI0181 Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active ra despite methotrexate therapy: Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2638 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 373.2-373 ◽

Cited By ~ 1

Author(s):

B. Hsu ◽

C.-F. Chiou ◽

S. Sheng ◽

J. Smolen ◽

M. Weinblatt

Keyword(s):

Monoclonal Antibody ◽

Physical Function ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Active Rheumatoid Arthritis ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

Download Full-text

SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.3239 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 684.3-685 ◽

Cited By ~ 1

Author(s):

S. Daniluk ◽

B.K. Skrumsager ◽

P. Leszczynski

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Multiple Dose ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Trial

Download Full-text

FRI0169 Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with results observed by 2 weeks: Results of the phase 3, multicenter, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2626 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 368.3-369

Author(s):

M.E. Weinblatt ◽

C.O. Bingham ◽

A.M. Mendelsohn ◽

L. Kim ◽

M. Mack ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Controlled Trial ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0024 Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1707 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 60.3-61

Author(s):

N. Damjanov ◽

M. Tlustochowicz ◽

J. Aelion ◽

A. Dimic ◽

M. Greenwald ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Download Full-text

Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-201411 ◽

2012 ◽

Vol 72 (3) ◽

pp. 381-389 ◽

Cited By ~ 60

Author(s):

Michael E Weinblatt ◽

Clifton O Bingham ◽

Alan M Mendelsohn ◽

Lilianne Kim ◽

Michael Mack ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-203742 ◽

2013 ◽

Vol 73 (12) ◽

pp. 2152-2159 ◽

Cited By ~ 18

Author(s):

Michael E Weinblatt ◽

Rene Westhovens ◽

Alan M Mendelsohn ◽

Lilianne Kim ◽

Kim Hung Lo ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Benefit ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text